Advertisement
Advertisement
ARMP
Armata Pharmaceuticals, Inc. Common Stock
4.54
USDSponsored
-0.24
-5.02%
Jul 31, 15:59 UTC -4
Closed
After-Market
4.57
+0.03
+0.55%
ARMP Earnings Reports
Positive Surprise Ratio
ARMP beat 20 of 40 last estimates.
50%
Next Report
Date of Next Report
Aug 18, 2026
Estimate for Q2 26 (Revenue/ EPS)
$428.40K
/-$0.45
Implied change from Q1 26 (Revenue/ EPS)
-45.70%
/-85.76%
Implied change from Q2 25 (Revenue/ EPS)
-80.25%
/--
Armata Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 13, 2026, ARMP reported earnings of -3.16 USD per share (EPS) for Q1 26, missing the estimate of -0.38 USD, resulting in a -715.27% surprise. Revenue reached 789.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a -7.03% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.45 USD, with revenue projected to reach 428.40 thousand USD, implying an decrease of -85.76% EPS, and decrease of -45.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
Myriad Genetics Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.25
Surprise
-323.73%
Crescent Biopharma, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.74
Surprise
+8.74%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.20%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.46
Actual
$14.29
Surprise
+36.51%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
PTC Therapeutics, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.42
Actual
$0.92
Surprise
+116.37%
FAQ
What were Armata Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Armata Pharmaceuticals, Inc. Common Stock reported EPS of -$3.16, missing estimates by -715.27%, and revenue of $789.00K, 0% as expectations.
How did the market react to Armata Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -7.03%, changed from $8.82 before the earnings release to $8.20 the day after.
When is Armata Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 18, 2026.
What are the forecasts for Armata Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, Armata Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.45 and revenue of $428.40K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement